Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Paganini%2C+Claudia%22&type=Person&sort=year
/vufind/Search/Results?lookfor=%22Paganini%2C+Claudia%22&type=Person&sort=year
Search /vufind/Search2/Results?lookfor=%22Paganini%2C+Claudia%22&type=Person&sort=year
PubPharm (11)
1
Evaluating the Clinical Meaning of Dermatology Life Quality Index Scores Between Different Phenotypes of Atopic Dermatitis in Patients Before and After Biologic Therapy With Dupilumab
enthalten in:
Dermatitis : contact, atopic, occupational, drug
| 2024
von
Russo, F.
|
Cioppa, V.
|
Lazzeri, L.
| +12
Wird geladen...
2
Efficacy and Safety of Dupilumab in the Treatment of Hand Eczema : A Retrospective Study
enthalten in:
Journal of clinical medicine
| 2024
von
Paganini, C.
|
Maffei, V.
|
Vellucci, L.
| +6
Wird geladen...
3
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors : A case series
enthalten in:
Journal of the European Academy of Dermatology and Venereology : JEADV
| 2024
von
Gori, N.
|
Ippoliti, E.
|
Ferrucci, S.
| +24
Wird geladen...
4
Dupilumab for Treatment of Prurigo Nodularis : Real-Life Effectiveness for up to 84 Weeks
enthalten in:
Journal of clinical medicine
| 2024
von
Paganini, C.
|
Talamonti, M.
|
Maffei, V.
| +3
Wird geladen...
5
Letter in response to the case report : "Recalcitrant generalized granuloma annulare treated successfully with dupilumab"
enthalten in:
JAAD case reports
| 2023
von
Paganini, C.
|
Talamonti, M.
|
Campione, E.
| +2
Wird geladen...
6
Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis
enthalten in:
Expert opinion on pharmacotherapy
| 2023
von
Galluzzo, M.
|
Vellucci, L.
|
Marcelli, L.
| +3
Wird geladen...
7
Guselkumab for treatment of moderate-to-severe plaque psoriasis : real-life effectiveness and drug-survival for up to 148 weeks
enthalten in:
Expert opinion on biological therapy
| 2023
von
Galluzzo, M.
|
Marcelli, L.
|
Vellucci, L.
| +6
Wird geladen...
8
Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate
enthalten in:
Wiener medizinische Wochenschrift (1946)
| 2022
von
Berek, K.
|
Paganini, C.
|
Hegen, H.
| +6
Wird geladen...
9
Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate
enthalten in:
Wiener medizinische Wochenschrift
| 2022
von
Berek, K.
|
Paganini, C.
|
Hegen, H.
| +6
Wird geladen...
10
Natalizumab treatment during pregnancy in multiple sclerosis—clinical and bioethical aspects of an ongoing debate
enthalten in:
Wiener medizinische Wochenschrift
| 2022
von
Berek, K.
|
Paganini, C.
|
Hegen, H.
| +6
Wird geladen...
1
2
Nächster »
[2]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
11
Aufsätze
10
E-Artikel
10
E-Ressourcen
1
Gedruckte Aufsätze
Zeitschriftentitel
3
Wiener medizinische Wochenschrift
2
Journal of clinical medicine
1
Dermatitis : contact, atopic, occupational, drug
1
Expert opinion on biological therapy
1
Expert opinion on pharmacotherapy
1
JAAD case reports
1
Journal of the European Academy of Dermatology ...
1
Wiener medizinische Wochenschrift (1946)
Alle anzeigen ...
weniger ...
Thema
7
Journal Article
4
Bioethics
4
Decision-making
4
Disease-modifying treatment
4
MS
4
Safety
3
dupilumab
2
atopic dermatitis
1
089658A12D
1
Antibodies, Monoclonal
1
BMS-986165
1
Case Reports
1
Deucravacitinib
1
EC 2.7.10.2
1
Heterocyclic Compounds
1
Immunologic Factors
1
Letter
1
N0A21N6RAU
1
Natalizumab
1
PASI
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4
2024
3
2023
4
2022
Erscheinungsjahr(e)
Von:
Bis:
Sprache
11
Englisch
Haven't found what you're looking for?
Wird geladen...